299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02029521
(ClinicalTrials.gov)
March 201130/12/2013Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis PatientsSupplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis for Growth FailureCystic FibrosisDietary Supplement: Oral reduced l-glutathione;Dietary Supplement: PlaceboClark BishopNULLCompleted18 Months10 YearsAll47N/AItaly
2NCT01450267
(ClinicalTrials.gov)
June 201030/9/2011Inhaled Glutathione (GSH) Versus Placebo in Cystic FibrosisRandomized, Single Blind, Controlled Trial of Inhaled Glutathione Versus Placebo in Patients With Cystic FibrosisCystic FibrosisDrug: Inhaled Reduced Glutathione;Drug: Physiological solutionSerafino A. MarsicoFederico II UniversityRecruiting6 Years45 YearsBoth150Phase 3Italy
3NCT00506688
(ClinicalTrials.gov)
July 200724/7/2007Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis PatientsRandomized, Placebo-controlled, Double-blinded Study to Investigate the Efficacy and Safety of a 24-week Inhalation Treatment With Glutathione in Cystic Fibrosis PatientsCystic FibrosisDrug: reduced glutathione sodium salt;Drug: 0.9% normal saline (control)Mukoviszidose Institut gGmbHCystic Fibrosis Foundation TherapeuticsCompleted8 YearsN/ABoth153Phase 2Germany
4EUCTR2005-003870-88-DE
(EUCTR)
20/10/200628/08/2006Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients - GSH-4Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients - GSH-4 Cystic fibrosis (CF) is the most common autosomal recessive lethal hereditary disorder in Caucasians. The majority of cystic fibrosis patients die as a result of progressive pulmonary disease. Airway inflammation, characterized by an excessive and persistent neutrophilic infiltration, is key for the pathogenesis of CF lung disease, and ultimately leads to lung destruction.Product Name: GSH (Glutathione)
Product Code: TAD 600
INN or Proposed INN: Glutathione
Other descriptive name: reduced glutathione
Mukoviszidose Institut gGmbH i. G.NULLNot RecruitingFemale: yes
Male: yes
160Germany